Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964744 | 0.84 | EPHX1 (0.39) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL1754047 | 0.84 | EPHX1 (0.41) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL20143489 | 0.82 | EPHX1 (0.35) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL19392024 | 0.80 | EPHX1 (0.39) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL9966002 | 0.80 | EPHX1 (0.39) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL21030685 | 0.78 | HPGD (0.41) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL19245616 | 0.78 | DPP4 (0.32) | DPP4TSHRPIK3CD | |
| SCHEMBL13575257 | 0.78 | POLB (0.43) | EPHX1KDM4ETP53KMT2ADPP4 | |
| SCHEMBL18977442 | 0.78 | POLB (0.43) | EPHX1KDM4ETP53KMT2ADPP4 | |
| SCHEMBL13575255 | 0.78 | POLB (0.43) | EPHX1KDM4ETP53KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | EPHX1 1340/4885HPGD 1024/4885L3MBTL1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.